S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
OTCMKTS:ARTH

Arch Therapeutics Stock Forecast, Price & News

$0.16
-0.01 (-2.98 %)
(As of 10/20/2020 03:59 PM ET)
Add
Compare
Today's Range
$0.16
Now: $0.16
$0.17
50-Day Range
$0.16
MA: $0.17
$0.18
52-Week Range
$0.12
Now: $0.16
$0.30
Volume311,104 shs
Average Volume304,055 shs
Market Capitalization$31.47 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.03
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Read More
Arch Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARTH
Previous SymbolNASDAQ:ARTH
CUSIPN/A
Phone617-431-2313
Employees8

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-4,550,000.00

Miscellaneous

Market Cap$31.47 million
Next Earnings Date10/22/2020 (Estimated)
OptionableNot Optionable
$0.16
-0.01 (-2.98 %)
(As of 10/20/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

How has Arch Therapeutics' stock price been impacted by Coronavirus?

Arch Therapeutics' stock was trading at $0.2050 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARTH shares have decreased by 20.5% and is now trading at $0.1630.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Arch Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arch Therapeutics
.

When is Arch Therapeutics' next earnings date?

Arch Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Arch Therapeutics
.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01.
View Arch Therapeutics' earnings history
.

What price target have analysts set for ARTH?

2 Wall Street analysts have issued 12-month target prices for Arch Therapeutics' shares. Their forecasts range from $1.25 to $1.50. On average, they expect Arch Therapeutics' share price to reach $1.38 in the next twelve months. This suggests a possible upside of 743.6% from the stock's current price.
View analysts' price targets for Arch Therapeutics
.

Are investors shorting Arch Therapeutics?

Arch Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 996,400 shares, an increase of 75.7% from the September 15th total of 567,000 shares. Based on an average trading volume of 656,600 shares, the short-interest ratio is currently 1.5 days.
View Arch Therapeutics' Short Interest
.

Who are some of Arch Therapeutics' key competitors?

What other stocks do shareholders of Arch Therapeutics own?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the following people:
  • Dr. Terrence W. Norchi, Co-Founder, Chairman, Pres, CEO & Sec. (Age 55, Pay $429.25k)
  • Mr. Richard E. Davis, CFO & Treasurer (Age 62, Pay $328.33k)
  • Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
  • Dr. Steven A. Kates Ph.D., VP of Technology
  • Dr. Elaine Whitmore, Regulatory Consultant & Advisor

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.16.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $31.47 million. Arch Therapeutics employs 8 workers across the globe.

What is Arch Therapeutics' official website?

The official website for Arch Therapeutics is www.archtherapeutics.com.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.